Nanogel antigen DDS toward overcoming immune resistance of cancer
-
- Harada Naozumi
- United Immunity, Co., Ltd.
-
- Muraoka Daisuke
- Graduate School of Medicine, Mie University
-
- Shiku Hiroshi
- Graduate School of Biomedical Sciences, Nagasaki University
-
- Akiyoshi Kazunari
- Graduate School of Engineering, Kyoto University
Bibliographic Information
- Other Title
-
- ナノゲル抗原DDSによる免疫療法抵抗性がんの克服に向けて
- ナノゲル コウゲン DDS ニ ヨル メンエキ リョウホウ テイコウセイ ガン ノ コクフク ニ ムケテ
Search this article
Description
In therapeutic cancer vaccine, it is important that vaccine antigen should be efficiently delivered at the appropriate time to antigen-presenting cells (dendritic cells and macrophages) located in lymphoid organs (lymph nodes and spleen) in order to induce higher anti-tumor immune response. We have developed novel cancer vaccines using cholesterol-substituted pullulan (CHP) nanogel as an antigen delivery system for targeted antigen delivery. In addition, recently we have proposed a new technology using CHP nanogel to regulate the functions of tumor-associated macrophages leading to the improvement of tumor microenvironment. When combined with other immunotherapies, modulation of macrophage function using CHP nanogel brings potent inhibitory effect on immune checkpoint inhibition-resistant cancer.
Journal
-
- Drug Delivery System
-
Drug Delivery System 35 (1), 64-69, 2020-01-25
THE JAPAN SOCIETY OF DRUG DELIVERY SYSTEM
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390003825176501248
-
- NII Article ID
- 130007835761
-
- NII Book ID
- AN10084591
-
- ISSN
- 18812732
- 09135006
-
- NDL BIB ID
- 030239859
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- NDL
- Crossref
- CiNii Articles
-
- Abstract License Flag
- Disallowed